Mr. McCaffrey is the co-founder, President and CEO of Zenith Capital Corp., a biotechnology investment company focused on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with significant unmet medical need. Zenith was spun out of Resverlogix Corp. (TSX: RVX) in 2013.
Don has over 38 years of corporate management experience including over 18 years in drug discovery & development. Don’s expertise in corporate operations has attracted an international team of experts to the company, including world renowned Key Opinion Leaders in the fields of oncology.
In addition to Zenith, Don serves as President, CEO and Chairman of Resverlogix Corp. (TSX: RVX), a pioneer in the landscape of epigenetics, currently conducting a global Phase 3 clinical trial – BETonMACE – with the most advanced epigenetic drug outside of oncology, apabetalone.
Don’s career accomplishments have been recognized by the business community and peers, as he was nominated for Ernst & Young Entrepreneur of the Year three times. He has also arranged support for several non-profit organizations, including: the Libin Cardiovascular Institute of Alberta, Juvenile Diabetes Research Foundation, Sanofi Biogenius Canada (MindFuel), United Way, Mount Royal University Foundation, Alberta Children's Hospital, Edge School Foundation, Education Matters, Calgary Urban Project Society Literacy Program, Movember Foundation, and Enbridge Ride to Conquer Cancer.